trpml

(1R,2R)-ML-SI3 ((-)-trans-ML-SI3) is a selective TRPML1, TRPML2, and TRPML3 inhibitor for the study of neurodegenerative and cardiovascular diseases.

AKOS037652256 can be used as a TRPML modulator for the treatment of diseases associated with TRPML activity such as lysosomal accumulation disorders, muscular dystrophy, common age-related neurodegenerative diseases, oxidative stress or reactive oxygen species (ROS)-related diseases and ageing.

2-benzylsulfanyl-6-methoxy-4-methylquinazoline can be used as a TRPML modulator for the treatment of diseases associated with TRPML activity, such as lysosomal storage disease, muscular dystrophy, oxidative stress or reactive oxygen species (ROS)-related diseases and ageing.

ML-SA1 (Mucolipin synthetic agonist 1) is a selective TRPML agonist, inhibits Dengue virus 2 (DENV2) and Zika virus (ZIKV) by promoting lysosomal acidification and protease activity. The IC50 value of ML-SA1 against DENV2 RNA and ZIKV RNA is 8.3 μM and 52.99 μM, respectively[1].

ML-SI1, a racemic mixture of diastereoisomers, is a TRPML inhibitor with an IC50 of 15 μM acting on TRPML1.

(1S,2S)-ML-SI3, the trans-isomer of ML-SI3, acts as a TRPML inhibitor. This (-)-isomer effectively inhibits TRPML1 and TRPML2 with IC 50 values of 1.6 μM and 2.3 μM, respectively, and exhibits weaker inhibition of TRPML3 with an IC 50 of 12.5 μM. In contrast, the (+)-enantiomer inhibits TRPML1 (IC 50 = 5.9 μM) and serves as an activator for TRPML2 and TRPML3 with EC 50 values of 2.7 μM and 10.8 μM respectively [1].'

ML-SI3 is an inhibitor of the TRPML family of calcium channels that selectively inhibits TRPML1, TRPML2, and TRPML3. ML-SI3 can be used to study neurodegenerative and cardiovascular diseases.